How much does Teclistamab cost in 2026? The latest market price

Teritusumab (Teclistamab-cqyv), the trade name in China is Teritusimab, is a drug for multiple myeloma (MM)'s bispecific antibody, which can simultaneously recognize the CD3 receptor on the surface of T cells and BCMA (B cell maturation antigen) on tumor cells, kills tumor cells by activating T cells, thus providing a new therapeutic strategy in the clinic. Due to their targeting mechanism and innovation, these drugs are high-end biologics globally and are therefore relatively expensive.

In the domestic market, teritusumab has been officially approved for marketing, but it has not yet been included in the medical insurance system. Each box is sold for approximately between 30,000 and 40,000 yuan. The specific price varies depending on the drug specifications and procurement channels. In overseas markets, the price of teritusumab also shows certain differences. For example, the European version of 30mg/3ml specification sells for about more than 10,000 yuan per box, while the 153mg/1.7ml (90mg/ml) specification may cost more than 50,000 yuan per box. Exchange rate fluctuations will affect the final price. This high pricing is mainly due to its high research and development costs, complex production processes and its uniqueness as an innovative biologic.

Currently, no generic version of teritusumab has yet been launched, either domestically or overseas. Therefore, patients mainly rely on original drugs for treatment selection. Whether it is financial burden or access channels, they need to plan in advance. Because the drug is administered intravenously or subcutaneously, supporting medical resources and care will also affect the overall treatment cost. It is important for patients and families to understand the drug's pricing structure, legal procurement channels, and healthcare provider support services to ensure safe and effective use of teritusumab.

In general, as an innovative drug for the treatment of multiple myeloma, teritusumab is relatively expensive, but its unique bispecific antibody mechanism provides patients with new treatment hope. Although it is not yet covered by medical insurance, its therapeutic value is still important in certain patient groups.

Reference materials:https://www.tecvayli.com/